Jan 28 (Reuters) – India’s Gland Pharma reported a nearly 28% jump in third-quarter profit on Wednesday, boosted by strong sales in the key European and U.S. markets.
The Hyderabad-based company reported a consolidated net profit of 2.61 billion rupees ($28.40 million) for the quarter ended December 31, from 2.05 billion rupees a year earlier.
Revenue from operations rose 22.5% to 16.95 billion rupees.
Its U.S. sales, which make up more than half of the total, rose 19%, while its Europe business posted a 54% rise.
For further results highlights, click
KEY CONTEXT
Gland Pharma and several Indian drugmakers that produce generic medicines derive a large share of their revenue from the U.S.
The company reported double-digit sales growth in the U.S., while its larger rivals Cipla and Dr. Reddy’s reported a decline due to intense competition during the period.
Gland Pharma’s Cenexi unit in France and Belgium also recovered from a production disruption that had affected it through much of 2025.
Cenexi’s strong revenue traction was a key contributor to the company’s consolidated performance in the quarter, CEO Shyamakant Giri said.
Earnings before interest, taxes, depreciation and amortisation (EBITDA) rose 21% in the quarter ended December compared to a year earlier.
PEER COMPARISON
Estimates Analysts’
(next 12 sentiment
months)
RI PE EV/ Reven Prof Mea # of Stock Div
C EBI ue it n anal to yiel
TDA growt grow rat ysts price d
h (%) th ing target (%)
(%) * **
Gland 23 13. 13.99 28.5 Hol 14 0.84 1.07
Pharma Ltd .8 53 9 d
3
Zydus 21 14. 7.27 -9.7 Hol 29 0.89 1.23
Lifescienc .2 31 8 d
es Ltd 5
Dr Reddy’s 21 13. 3.37 -10. Hol 39 0.92 0.65
Laboratori .6 06 20 d
es Ltd 1
Cipla Ltd 23 14. 7.73 0.21 Hol 37 0.90 0.99
.3 92 d
3
* Mean of analysts’ ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell
** Ratio of the stock’s last close to analysts’ mean price target; a ratio above 1 means the stock is trading above the PT
OCTOBER TO DECEMBER STOCK PERFORMANCE
— All data from LSEG
— $1 = 91.8990 Indian rupees
(Reporting by Kashish Tandon and Nishit Navin in Bengaluru; Editing by Harikrishnan Nair)
Comments